Yes and when a cashed up inexperienced CEO meets Paul Hopper he is quickly relieved of it. The same board that sacked Kelly now sacks the guy they appointed after they have destroyed shareholder value. Further they said they were not going early stage then they bought a phase I. If you don't stand for something you fall for anything. All these trials that took only $500K and a free drug without obligations. So many trials running for years but no progress to report. They should put Dunn as chair that guy puts them to shame.
KZA Price at posting:
19.5¢ Sentiment: Hold Disclosure: Held
